📊 XERS Key Takeaways
Is Xeris Biopharma Holdings, Inc. (XERS) a Good Investment?
Xeris demonstrates strong operational momentum with 43.7% revenue growth and exceptional 101% net income improvement, supported by positive free cash flow of $8.8M and a solid $111.8M cash position. However, severe balance sheet leverage (17.0x debt-to-equity) and critically low interest coverage (1.1x) create significant financial risk that must be addressed through debt reduction or substantial margin expansion before a positive recommendation is warranted.
Xeris Biopharma Holdings, Inc. Key Strengths (XERS)
- Strong revenue growth of 43.7% YoY demonstrating market demand and product traction
- Exceptional net income growth of 101% YoY showing operational leverage improving
- Robust cash position of $111.8M providing financial flexibility and runway
- Positive free cash flow generation of $8.8M with 10.6% FCF margin
- Healthy liquidity ratios (Current 2.12x, Quick 1.50x) supporting short-term obligations
XERS Stock Risks: Xeris Biopharma Holdings, Inc. Investment Risks
- Dangerously high leverage with 17.0x debt-to-equity ratio concentrated in $221.2M long-term debt
- Critically low interest coverage ratio of 1.1x providing minimal cushion for debt service disruption
- Extremely thin net profit margin of 2.7% limiting operational error tolerance
- Severely undercapitalized equity base ($13.0M) relative to $379.0M liabilities creates solvency concerns
- Pharmaceutical sector regulatory, patent, and competitive risks could impair revenue sustainability
Key Metrics to Watch
- Interest coverage ratio - must improve above 2.0x for adequate debt service capacity
- Debt reduction and debt-to-equity ratio - trajectory toward <5.0x is critical
- Net profit margin expansion - pathway to sustain growth without additional leverage
- Operating cash flow consistency - essential for meeting interest obligations and refinancing
Xeris Biopharma Holdings, Inc. (XERS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
XERS Profit Margin, ROE & Profitability Analysis
XERS vs Healthcare Sector: How Xeris Biopharma Holdings, Inc. Compares
How Xeris Biopharma Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xeris Biopharma Holdings, Inc. Stock Overvalued? XERS Valuation Analysis 2026
Based on fundamental analysis, Xeris Biopharma Holdings, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xeris Biopharma Holdings, Inc. Balance Sheet: XERS Debt, Cash & Liquidity
XERS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xeris Biopharma Holdings, Inc.'s revenue has grown significantly by 492% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.45 indicates the company is currently unprofitable.
XERS Revenue Growth, EPS Growth & YoY Performance
XERS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $60.1M | $2.2M | $0.01 |
| Q3 2025 | $54.3M | $621.0K | $0.00 |
| Q2 2025 | $48.1M | -$1.9M | $-0.01 |
| Q1 2025 | $40.6M | -$9.2M | $-0.06 |
| Q3 2024 | $48.3M | -$12.2M | $-0.09 |
| Q2 2024 | $38.0M | -$15.0M | $-0.10 |
| Q3 2023 | $29.7M | -$12.2M | $-0.09 |
| Q3 2022 | $11.1M | -$18.4M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xeris Biopharma Holdings, Inc. Dividends, Buybacks & Capital Allocation
XERS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xeris Biopharma Holdings, Inc. (CIK: 0001867096)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XERS
What is the AI rating for XERS?
Xeris Biopharma Holdings, Inc. (XERS) has an AI grade of B with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XERS's key strengths?
Claude: Strong revenue growth of 43.7% YoY demonstrating market demand and product traction. Exceptional net income growth of 101% YoY showing operational leverage improving.
What are the risks of investing in XERS?
Claude: Dangerously high leverage with 17.0x debt-to-equity ratio concentrated in $221.2M long-term debt. Critically low interest coverage ratio of 1.1x providing minimal cushion for debt service disruption.
What is XERS's revenue and growth?
Xeris Biopharma Holdings, Inc. reported revenue of $83.1M.
Does XERS pay dividends?
Xeris Biopharma Holdings, Inc. does not currently pay dividends.
Where can I find XERS SEC filings?
Official SEC filings for Xeris Biopharma Holdings, Inc. (CIK: 0001867096) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XERS's EPS?
Xeris Biopharma Holdings, Inc. has a diluted EPS of $0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is XERS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Xeris Biopharma Holdings, Inc. has a B grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is XERS stock overvalued or undervalued?
Valuation metrics for XERS: ROE of 17.2% (sector avg: 15%), net margin of 2.7% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is XERS's AI grade for 2026?
Our dual AI analysis gives Xeris Biopharma Holdings, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XERS's free cash flow?
Xeris Biopharma Holdings, Inc.'s operating cash flow is $9.9M, with capital expenditures of $1.1M. FCF margin is 10.6%.
How does XERS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2.7% (avg: 12%), ROE 17.2% (avg: 15%), current ratio 2.12 (avg: 2).
Is Xeris Biopharma Holdings, Inc. carrying too much debt?
XERS has a debt-to-equity ratio of 17.00x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.12 suggests adequate short-term liquidity.